X4 Pharmaceuticals (XFOR) Capital Expenditures (2017 - 2024)

X4 Pharmaceuticals' Capital Expenditures history runs 8 years deep, the most recent figure standing at $41000.0 for Q4 2024.

• Quarterly Capital Expenditures changed N/A year-over-year to $41000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $41000.0 (down 85.61% YoY) and the FY2024 annual result came in at $326000.0, changed N/A from the prior year.
• Capital Expenditures was $41000.0 for Q4 2024 at X4 Pharmaceuticals, down from $92000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.5 million in Q3 2020 and bottomed at -$690000.0 in Q4 2020.
• A 5-year average of $133666.7 and a median of $36000.0 in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2020 — Capital Expenditures jumped 1737.04% — and 2021, when it plunged 5611.11%.
• X4 Pharmaceuticals' Capital Expenditures stood at -$690000.0 in 2020, then jumped by 101.88% to $13000.0 in 2021, then surged by 161.54% to $34000.0 in 2022, then plunged by 126.47% to -$9000.0 in 2023, then surged by 555.56% to $41000.0 in 2024.
• Business Quant data shows XFOR's Capital Expenditures at $41000.0 in Q4 2024, $92000.0 in Q3 2024, and $134000.0 in Q2 2024.